Special Issue

Veterinary Vaccines and Host Immune Responses

Message from the Guest Editors

The emergence of new and re-emerging infectious diseases that threaten animal populations worldwide and public health requires continuous improvement in vaccine efficacy, safety, and delivery methods. The development of novel vaccine platforms, including subunit, mRNA, and vectored vaccines, enhances the specificity and durability of immune responses in animals, thus providing effective disease prevention. The use of adjuvants in combination with vaccines has also been explored over the decades. Improved adjuvant applications boost immune responses in animals with minimum antigen content, contributing to cost-effective vaccine development, Recent technologies have shed light on the mechanisms of immune responses and molecular interactions that enable the development of more targeted and effective vaccines.

In this Special Issue, we invite original research articles and review articles in the context of recent advancements and ongoing research in veterinary immunology and vaccine development.

Guest Editors

Dr. Ayumi Matsuyama-Kato

Department of Veterinary Pathology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada

Prof. Dr. Faizal Careem

Faculty of Veterinary Medicine, University of Calgary, Calgary, AB T2N 1N4. Canada

Deadline for manuscript submissions

13 August 2025



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/214025

Vaccines Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

